See today's BioWorld Science
To read the full story, subscribe or sign in.
Endocrine/metabolic

Amylyx and Gubra collaborate to develop long-acting GLP-1 receptor antagonist

Dec. 31, 2024
Amylyx Pharmaceuticals Inc. and Gubra A/S have established a collaboration for the development of a novel long-acting GLP-1 receptor antagonist.
BioWorld Science Collaboration Endocrine/metabolic Peptide